Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?

被引:86
|
作者
Boer, J. [1 ]
Nazary, M. [2 ]
机构
[1] Deventer Hosp, Dept Dermatol, NL-7416 SE Deventer, Netherlands
[2] Univ Utrecht, NL-3584 CA Utrecht, Netherlands
关键词
ISOTRETINOIN; RETINOIDS; LESIONS; ETRETINATE; EFFICACY;
D O I
10.1111/j.1365-2133.2010.10071.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Background Hidradenitis suppurativa (HS) is a distressing chronic inflammatory skin disorder which affects predominantly the groins and axillae. In analogy to acne, oral isotretinoin has been considered in the treatment of HS, although there are strong indications that this drug has only a very limited therapeutic effect. During the past 25 years scattered case reports have described promising results of treatment with acitretin. Objectives To evaluate the long-term efficacy of acitretin monotherapy. Methods A retrospective study in 12 patients with severe, recalcitrant HS who were treated with acitretin for 9-12 months at one Dermatology Centre in the Netherlands between 2005 and 2007 and were followed up to 4 years. The patients were men and infertile women. The efficacy of the treatment was rated by the patients on global maximum pain of nodules and abscesses on a visual analogue scale (VAS) as well as by physician global assessment. Results All 12 patients achieved remission and experienced a significant decrease in pain as assessed by VAS. In nine patients long-lasting improvement was observed, with no recurrence of lesions after 6 months (n = 1), 1 year (n = 3), > 2 years (n = 2), > 3 years (n = 2) and > 4 years (n = 1). Conclusions Acitretin appears to be an effective treatment for refractory HS, leading to reduction of pain from painful nodules and reducing the extent of the disease for a prolonged period.
引用
收藏
页码:170 / 175
页数:6
相关论文
共 50 条
  • [1] Hidradenitis suppurativa is acne inversa! An appeal to (finally) abandon a misnomer
    Sellheyer, K
    Krahl, D
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2005, 44 (07) : 535 - 540
  • [2] Acne inversa (hidradenitis suppurativa): From diagnosis to therapy [Acne inversa (Hidradenitis suppurativa): Erkennen - Verstehen - Therapieren]
    Mühlstädt M.
    Bechara F.G.
    Kunte C.
    Der Hautarzt, 2013, 64 (1): : 55 - 62
  • [3] Acne inversa (hidradenitis suppurativa). From diagnosis to therapy
    Muehlstaedt, M.
    Bechara, F. G.
    Kunte, C.
    HAUTARZT, 2013, 64 (01): : 55 - 61
  • [4] Acne inversa/Hidradenitis suppurativa - From Pathogenesis to Therapy
    Schuch, A.
    Absmaier-Kijak, M.
    Volz, T.
    AKTUELLE DERMATOLOGIE, 2019, 45 (06) : 277 - 287
  • [5] Acne inversa - Good long-term results due to radical surgical excision [Die Acne inversa (Hidradenitis suppurativa): Frühzeitig erkennen und kurativ operieren]
    Herrmann A.
    Preusser K.-P.
    Marsch W.Ch.
    Der Chirurg, 2000, 71 (11): : 1395 - 1400
  • [6] Photodynamic therapy for Hidradenitis Suppurativa/acne inversa: Case report
    Zhang, Yunjie
    Yang, Yuguang
    Zou, Xianbiao
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2018, 22 : 251 - 252
  • [7] Hidradenitis Suppurativa (Acne inversa) - Current Status on Comorbidity and Therapy
    Wilden, S.
    Schepler, H.
    von Stebut, E.
    AKTUELLE DERMATOLOGIE, 2018, 44 (03) : 92 - 99
  • [8] Guselkumab as an Anti Inflammatory Therapy Option for the Treatment of severe Hidradenitis suppurativa/Acne inversa
    Brown, V
    Scholl, L.
    Segert, M. H.
    Bechara, F. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 171 - 171
  • [9] Long-wave Medical Infrared Thermography assessment of inflammation in hidradenitis suppurativa/acne inversa
    Zouboulis, C. C.
    da Costa, A. N.
    Jemec, G. B.
    Trebing, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S236 - S236
  • [10] High Dose of Ustekinumab for Patients with severe, therapy-resistant Hidradenitis suppurativa/Acne inversa
    Scholl, L.
    Segert, M. H.
    Brown, V
    Hessam, S.
    Bechara, F. G.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 145 - 145